Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $3
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $4 to $3.
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $4 to $3.